Somatic mutations analyses revealed high levels of TP53, IDH1 and ATRX mutations in younger GBM patients, while late onset was characterized by amplification of dedicated oncogenes such as PIK3CA. IDH1 mutation in GBM have been reported to be associated with better prognosis [14]. This evidence concerns the gene TP53 and glioblastoma.